A Phase 3 interventional study of Atezolizumab and Bevacizumab in Carcinoma, Hepatocellular, sponsored by Hoffmann-La Roche. Completed at 134 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing atezolizumab in Carcinoma, Hepatocellular — 17 open to participants now, 29 under way, 7 of them phase 3. atezolizumab · Carcinoma, Hepatocellular.
Among the 41 studies testing atezolizumab in Carcinoma, Hepatocellular, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 11 in phase 3, and was the 4th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →17 of the 41 studies testing atezolizumab in Carcinoma, Hepatocellular are open now, in 11 countries. Recruiting first, the newest first:
Fundacion Clinic per a la Recerca Biomédica · Sites in Spain
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–90
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–75
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, atezolizumab is the treatment under test here. Read study by study →
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 21 · Phase 3 12 · Phase 4 2
First in 2017; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 668 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 40 across the 41 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 41 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
21 studies in Carcinoma, Hepatocellular by Hoffmann-La Roche: 1 open now, 6 under way, 3 of them phase 3. Of 15 finished, 6 (40%) have results posted.
Among the 21 studies in Carcinoma, Hepatocellular by Hoffmann-La Roche, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2019, is one of 7 in phase 3, and was the 10th registered.
Hoffmann-La Roche’s Carcinoma, Hepatocellular studies by the year they started, since 2005.
10 of the studies testing atezolizumab in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04803994Phase 3Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | 2027-07 |
| NCT07192185Sun Yat-sen UniversitySystemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab | 2026-12-01 |
| NCT06066138National Cancer Institute (NCI)A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | 2027-01-31 |
| NCT05377034National Cancer Centre, SingaporeMultinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients | 2027-02-15 |
| NCT05516628National Cancer Centre, SingaporeDeep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 41 studies testing atezolizumab in Carcinoma, Hepatocellular, from their registry updates:
Among Hoffmann-La Roche’s 21 in Carcinoma, Hepatocellular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Atezolizumab + Bevacizumab until disease recurrence or unacceptable toxicity.
Drug: Atezolizumab · Drug: Bevacizumab
Active surveillance of participants.
Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
Also known as: Tecentriq
Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Also known as: Avastin
Recurrence-Free Survival (RFS), as Determined by IRF
RFS is defined as the time from randomization to the first documented occurrence of intrahepatic or extrahepatic HCC as determined by an IRF, or death from any cause (whichever occurs first).
Time frame: Baseline up to approximately 33 months
Overall Survival (OS)
OS is defined as the time from randomization to death from any cause.
Time frame: Baseline up to approximately 91 months
RFS as Determined by the Investigator
RFS is defined as the time from randomization to the first documented occurrence of intrahepatic or extrahepatic HCC as determined by an investigator, or death from any cause (whichever occurs first).
Time frame: Baseline up to approximately 91 months
Time to Recurrence (TTR)
TTR defined as the time from randomization to first documented occurrence of intrahepatic or extrahepatic HCC, as determined by the investigator and by an IRF.
Time frame: Baseline up to approximately 91 months
RFS Rate at 24 and 36 Months, as Assessed by the IRF
Time frame: Randomization up to 24 months and up to 36 months
RFS Rate at 24 and 36 Months, as Assessed by the Investigator
Time frame: Randomization up to 24 months and up to 36 months
OS Rate at 24 and 36 Months
OS rate defined as the proportion of patients who have not experienced death from any cause at 24 and 36 months after randomization.
Time frame: Baseline to 24 and 36 months
Time to Extrahepatic Spread (EHS) or Macrovascular Invasion
Time to EHS or macrovascular invasion after randomization, defined as the time from randomization to the first appearance of EHS or macrovascular invasion, as determined by the investigator.
Time frame: Baseline up to approximately 91 months
RFS in Pd-L1-High Subgroup
RFS after randomization as determined by the investigator and by an IRF, among patients in the PD-L1-high subgroup.
Time frame: Baseline up to approximately 91 months
Percentage of Participants With Adverse Events
Time frame: Baseline up to approximately 91 months
Serum Concentration of Atezolizumab
Serum concentration of atezolizumab.
Time frame: Prior to any drug administration on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16, and 30 minutes after end of atezolizumab infusion on Day 1 of Cycle 1 (each cycle is 21 days)
Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
Number of participants with anti-drug antibodies to atezolizumab.
Time frame: Prior to any drug administration up to approximately 33 month
This study was conducted at 134 centers in 26 countries/regions.
| Milestone | Active Surveillance | Atezolizumab + Bevacizumab |
|---|---|---|
| Started | 334 | 334 |
| Completed | 0 | 0 |
| Not completed | 334 | 334 |
| Withdrew: Ongoing in study | 302 | 291 |
| Withdrew: Death | 20 | 27 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 11 | 14 |
| Milestone | Active Surveillance | Atezolizumab + Bevacizumab |
|---|---|---|
| Started | 81 | 0 |
| Completed | 0 | 0 |
| Not completed | 81 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Death | 11 | 0 |
| Withdrew: Ongoing in study | 69 | 0 |
RFS is defined as the time from randomization to the first documented occurrence of intrahepatic or extrahepatic HCC as determined by an IRF, or death from any cause (whichever occurs first).
| Months | Arm B (Active Surveillance) | Arm A (Atezolizumab Plus Bevacizumab) |
|---|---|---|
| Recurrence-Free Survival (RFS), as Determined by IRF | NA (21.4 to NA) | NA (22.1 to NA) |
OS is defined as the time from randomization to death from any cause.
Results for this outcome have not been posted.
RFS is defined as the time from randomization to the first documented occurrence of intrahepatic or extrahepatic HCC as determined by an investigator, or death from any cause (whichever occurs first).
Results for this outcome have not been posted.
TTR defined as the time from randomization to first documented occurrence of intrahepatic or extrahepatic HCC, as determined by the investigator and by an IRF.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
OS rate defined as the proportion of patients who have not experienced death from any cause at 24 and 36 months after randomization.
Results for this outcome have not been posted.
Time to EHS or macrovascular invasion after randomization, defined as the time from randomization to the first appearance of EHS or macrovascular invasion, as determined by the investigator.
Results for this outcome have not been posted.
RFS after randomization as determined by the investigator and by an IRF, among patients in the PD-L1-high subgroup.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Serum concentration of atezolizumab.
| μg/ mL | Arm A (Atezolizumab Plus Bevacizumab) |
|---|---|
| Cycle 1 Day 1 | NA ± NA |
| Cycle 1 Day 1, 30 Min After End of Atezo | 440 ± 132 |
| Cycle 2 Day 1 | 88.7 ± 30.4 |
| Cycle 3 Day 1 | 137 ± 53.0 |
| Cycle 4 Day 1 | 159 ± 58.5 |
| Cycle 8 Day 1 | 196 ± 86.2 |
| Cycle 12 Day 1 | 202 ± 90.1 |
| Cycle 16 Day 1 | 204 ± 89.2 |
Number of participants with anti-drug antibodies to atezolizumab.
| Participants | Arm A (Atezolizumab Plus Bevacizumab) |
|---|---|
| Baseline evaluable participants | 8 |
| Post-baseline evaluable participants | 75 |
Collected over From the first study drug administration to the data cutoff date: 21 October 2022 (up to approximately 33 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Surveillance | 20/334 (6%) | 34/330 (10.3%) | 111/330 (33.6%) |
| Atezolizumab+Bevacizumab | 27/334 (8.1%) | 80/332 (24.1%) | 296/332 (89.2%) |
| Crossover: Atezolizumab+Bevacizumab | 11/81 (13.6%) | 10/81 (12.3%) | 63/81 (77.8%) |
| Event | Active Surveillance | Atezolizumab+Bevacizumab | Crossover: Atezolizumab+Bevacizumab |
|---|---|---|---|
| PyrexiaGeneral disorders | 0/330 | 1/332 | 3/81 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 2/330 | 5/332 | 0/81 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/330 | 0/332 | 1/81 |
| Thrombotic microangiopathyBlood and lymphatic system disorders | 0/330 | 0/332 | 1/81 |
| Cardiac failureCardiac disorders | 0/330 | 1/332 | 1/81 |
| Cardiac failure congestiveCardiac disorders | 0/330 | 0/332 | 1/81 |
| HaemorrhoidsGastrointestinal disorders | 0/330 | 0/332 | 1/81 |
| HerniaGeneral disorders | 0/330 | 0/332 | 1/81 |
| Anaphylactic reactionImmune system disorders | 1/330 | 0/332 | 1/81 |
| Upper respiratory tract infectionInfections and infestations | 0/330 | 1/332 | 1/81 |
| Event | Active Surveillance | Atezolizumab+Bevacizumab | Crossover: Atezolizumab+Bevacizumab |
|---|---|---|---|
| ProteinuriaRenal and urinary disorders | 12/330 | 153/332 | 25/81 |
| HypertensionVascular disorders | 10/330 | 126/332 | 25/81 |
| Platelet count decreasedInvestigations | 22/330 | 66/332 | 17/81 |
| Aspartate aminotransferase increasedInvestigations | 18/330 | 51/332 | 13/81 |
| Alanine aminotransferase increasedInvestigations | 18/330 | 46/332 | 12/81 |
| HypothyroidismEndocrine disorders | 1/330 | 47/332 | 9/81 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/330 | 40/332 | 8/81 |
| PruritusSkin and subcutaneous tissue disorders | 3/330 | 40/332 | 6/81 |
| RashSkin and subcutaneous tissue disorders | 1/330 | 40/332 | 9/81 |
| PyrexiaGeneral disorders | 7/330 | 33/332 | 6/81 |
| Age, Continuous(Years) | Arm B (Active Surveillance) | Arm A (Atezolizumab Plus Bevacizumab) | Total |
|---|---|---|---|
| Mean | 58.9 ± 12.5 | 59.0 ± 12.1 | 59.0 ± 12.3 |
| Sex: Female, Male(Participants) | Arm B (Active Surveillance) | Arm A (Atezolizumab Plus Bevacizumab) | Total |
|---|---|---|---|
| Female | 56 | 57 | 113 |
| Male | 278 | 277 | 555 |
| Race (NIH/OMB)(Participants) | Arm B (Active Surveillance) | Arm A (Atezolizumab Plus Bevacizumab) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 4 |
| Asian | 269 | 276 | 545 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 1 | 2 | 3 |
| White | 41 | 35 | 76 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 21 | 16 | 37 |
Showing the first 100 of 134 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Dec 2019 to primary completion in Oct 2022, 33 months.
Results were first posted in Nov 2023, 1 year after primary completion.
Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 33 months is below that.
Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atezolizumab · Bevacizumab